<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; United States</title>
	<atom:link href="http://www.tapanray.in/tag/united-states/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Big Pharma Fails Avoiding Drug Price ‘Control’? Even In The US? Why?</title>
		<link>http://www.tapanray.in/big-pharma-fails-avoiding-drug-price-control-even-in-the-us-why/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-fails-avoiding-drug-price-control-even-in-the-us-why</link>
		<comments>http://www.tapanray.in/big-pharma-fails-avoiding-drug-price-control-even-in-the-us-why/#comments</comments>
		<pubDate>Mon, 22 Aug 2022 00:00:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[deals. Authorized]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eldorado]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[generics competition]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pay-for-delay]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thicket]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10699</guid>
		<description><![CDATA[It ultimately happened &#8211; even in the United States, as the US President signed a bill on August 16, 2022 that aims to reduce healthcare costs, alongside fighting climate change, besides raising taxes on the rich. This new law was enacted, despite &#8230; <a href="http://www.tapanray.in/big-pharma-fails-avoiding-drug-price-control-even-in-the-us-why/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-fails-avoiding-drug-price-control-even-in-the-us-why/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Shifting Pharma Supply Chain Strategy From Global To Local</title>
		<link>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shifting-pharma-supply-chain-strategy-from-global-to-local</link>
		<comments>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/#comments</comments>
		<pubDate>Mon, 08 Jun 2020 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lobbyists]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Procurement]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reevaluating]]></category>
		<category><![CDATA[shifting]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vulnerability]]></category>
		<category><![CDATA[Vulnerable]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10120</guid>
		<description><![CDATA[Alongside large-scale disruptions of many critical industrial operations, Covid-19 global pandemic took the wind out of the sail of pharma supply chain, as well, at the very onset of lockdowns. This happened in many countries around the world, including the &#8230; <a href="http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Opioid Crisis: A Looming Threat To India?</title>
		<link>http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=opioid-crisis-a-looming-threat-to-india</link>
		<comments>http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/#comments</comments>
		<pubDate>Mon, 16 Sep 2019 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[Atypical]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[emergency]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[flip side]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[looming]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[narcotics]]></category>
		<category><![CDATA[Nexus]]></category>
		<category><![CDATA[Opioid]]></category>
		<category><![CDATA[pain]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[tryst]]></category>
		<category><![CDATA[United States]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9712</guid>
		<description><![CDATA[A serious, but a typical health crisis that has shaken America, is now, apparently, in search of its prey in India – a soft target to ignite a raging fire of misuse or abuse of prescription drugs of addictive in &#8230; <a href="http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Continues ‘The Cat And Mouse Game’ In Pharma Business?</title>
		<link>http://www.tapanray.in/continues-the-cat-and-mouse-game-in-pharma-business/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=continues-the-cat-and-mouse-game-in-pharma-business</link>
		<comments>http://www.tapanray.in/continues-the-cat-and-mouse-game-in-pharma-business/#comments</comments>
		<pubDate>Mon, 24 Jun 2019 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Americans]]></category>
		<category><![CDATA[anti-trust]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[cat]]></category>
		<category><![CDATA[cat and mouse game]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[competitive]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[evade]]></category>
		<category><![CDATA[fixing]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[lawsuit]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[mouse]]></category>
		<category><![CDATA[ooff the cuff]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[price-fixing]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[wrongdoing]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9601</guid>
		<description><![CDATA[Many are already aware of the critical factors that make generic drugs so important for patients &#8211; virtually for all. These don’t just facilitate greater access to health care &#8211; offering affordable alternatives to high-priced off-patent innovative drugs. This is &#8230; <a href="http://www.tapanray.in/continues-the-cat-and-mouse-game-in-pharma-business/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/continues-the-cat-and-mouse-game-in-pharma-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilar Drugs: Why Prescriptions Aren’t Still Enough?</title>
		<link>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-why-prescriptions-arent-still-enough</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/#comments</comments>
		<pubDate>Mon, 14 Sep 2015 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[filgrastim]]></category>
		<category><![CDATA[filgrastim-sndz]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Hatch-Waxman]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[M&M]]></category>
		<category><![CDATA[marketsandmarkets]]></category>
		<category><![CDATA[Neupogen]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[QuantiaMD]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Similar]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Zarxio]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7055</guid>
		<description><![CDATA[On September 3, 2015, in a Press Release, Novartis announced, “Zarxio(TM) (filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to launch in the &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cancer Cure: Inching Towards The ‘Holy Grail’?</title>
		<link>http://www.tapanray.in/cancer-cure-inching-towards-the-holy-grail/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=cancer-cure-inching-towards-the-holy-grail</link>
		<comments>http://www.tapanray.in/cancer-cure-inching-towards-the-holy-grail/#comments</comments>
		<pubDate>Mon, 31 Aug 2015 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Carter]]></category>
		<category><![CDATA[cells]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[cure]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[former]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[Holy-Grail]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jimmy]]></category>
		<category><![CDATA[magic bullet]]></category>
		<category><![CDATA[Mayo Clinic]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[programming]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[re-programming]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United States]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6992</guid>
		<description><![CDATA[In a Press Conference on August 20, 2015, the 39th President of the United States, now 90-year-old  Jimmy Carter, revealed (video) that during a liver surgery earlier this month the doctors diagnosed that he has cancer. The type of cancer that he &#8230; <a href="http://www.tapanray.in/cancer-cure-inching-towards-the-holy-grail/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/cancer-cure-inching-towards-the-holy-grail/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Higher The Healthcare  Spend, Better The Healthcare Performance: A Myth?</title>
		<link>http://www.tapanray.in/higher-the-healthcare-spend-better-the-healthcare-performance-a-myth/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=higher-the-healthcare-spend-better-the-healthcare-performance-a-myth</link>
		<comments>http://www.tapanray.in/higher-the-healthcare-spend-better-the-healthcare-performance-a-myth/#comments</comments>
		<pubDate>Mon, 23 Jun 2014 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[better]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[commonwealth]]></category>
		<category><![CDATA[eleven]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Fund]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[higher]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[linear]]></category>
		<category><![CDATA[Myth]]></category>
		<category><![CDATA[nations]]></category>
		<category><![CDATA[New Zealand]]></category>
		<category><![CDATA[optimal]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[spend]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[wealthy]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5542</guid>
		<description><![CDATA[It is generally believed, higher the per-capita expenditure of healthcare, better is the overall ‘healthcare performance’ of a nation. However, this myth has recently been busted by a new study, the take-home message of which would be quite relevant for &#8230; <a href="http://www.tapanray.in/higher-the-healthcare-spend-better-the-healthcare-performance-a-myth/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/higher-the-healthcare-spend-better-the-healthcare-performance-a-myth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
